Becton Dickinson and Company (BDX)
Becton Dickinson and Company (BDX) carries a ŷRobot AI score of 47 out of 100. The model's fair value estimate is $179.55, 6.3% below the last close of $191.54. The chart signal reads Sell.
| Metric | BDX |
|---|---|
| AI score | 47 / 100 |
| Chart signal | Sell |
| Fair value estimate | $179.55 |
| Upside to fair value | -6.3% |
| Previous close | $191.54 |
| P/E | 31.46 |
| Price / sales | 2.16 |
| Market cap | $51.45B |
| EPS | 5.69 |
| Revenue growth | 4.8% |
| 1-year price change | -1.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about BDX
Is BDX overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Becton Dickinson and Company (BDX) at $179.55 against a last close of $191.54, implying 6.3% downside to the model's estimate.
Is BDX's chart signal bullish or bearish?
The chart-signal model classifies BDX as Neutral as of Oct 16, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is BDX's ŷRobot AI score?
BDX scores 47 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is BDX stock expensive on P/E and P/S?
BDX trades at 31.5 times earnings and 2.2 times sales as of Oct 16, 2026.
What does BDX's seasonal forecast show?
ŷRobot's seasonal forecast curve for BDX reads -1.1% at 30 days, +1.2% at 90 days, and -1.7% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BDX growing?
Becton Dickinson and Company's revenue growth is +4.8% and free-cash-flow growth is -6.8% on the latest reported figures.
BDX chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.